Zalicus Inc Com (NASDAQ:ZLCS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Recs

0
Player Avatar pchop123 (76.53) Submitted: 8/2/2012 3:55:34 PM : Outperform Start Price: $1.12 ZLCS Score: +16.30

nice pipeline of opportunities to be realized

Featured Broker Partners


Advertisement